naltrexone has been researched along with cyprodime in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 8 (28.57) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 11 (39.29) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Burkard, WP; Eggstein-Aeppli, L; Schmidhammer, H; Smith, CF | 1 |
| Aschenbach, LC; Cassidy, MP; Chen, J; Dewey, WL; Gabra, BH; Li, G; Selley, DE; Stevens, DL; Westkaemper, RB; Zhang, Y | 1 |
| Aschenbach, LC; He, H; Li, G; Selley, DE; Zhang, Y | 1 |
| Beletskaya, IO; Elbegdorj, O; Selley, DE; Yuan, Y; Zhang, Y | 1 |
| Arnatt, CK; He, H; Kellogg, GE; Mosier, PD; Selley, DE; Zaidi, SA; Zhang, Y | 1 |
| Aschenbach, LC; Dewey, WL; Elbegdorj, O; Li, G; Scoggins, KL; Selley, DE; Stevens, DL; Yuan, Y; Zaidi, SA; Zhang, Y | 1 |
| Jackson, HC; Nutt, DJ | 1 |
| Cosentino, M; De Ponti, F; Frigo, G; Giaroni, C; Lecchini, S; Leoni, O; Marino, F; Somaini, L | 1 |
| Spanagel, R | 1 |
| Chen, SF; Ghanta, VK; Hiramoto, RN; Hsueh, CM; Huang, HJ | 1 |
| Józefowski, S; Płytycz, B | 1 |
| Hata, F; Nishio, H; Nishiwaki, H; Saitoh, N; Takeuchi, T | 1 |
| Amico, MC; Mattioli, F; Morrone, LA; Romanelli, L; Valeri, P | 1 |
| Borsodi, A; Garzon, J; Hutcheson, DM; Maldonado, R; Rodriguez-Diaz, M; Roques, BP; Sánchez-Blazquez, P; Schmidhammer, H | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B | 1 |
| Dannals, RF; Mathews, WB; Musachio, JL; Ravert, HT; Scheffel, U | 1 |
| Aimi, N; Horie, S; Ishikawa, H; Matsumoto, K; Murayama, T; Ponglux, D; Takayama, H; Watanabe, K | 1 |
| Baamonde, A; García, V; Hidalgo, A; Juárez, L; Lastra, A; Menéndez, L | 1 |
| Assreuy, AM; Benevides, RG; Cavada, BS; Celedônio, NR; Coelho-de-Souza, AN; de Freitas Pires, A; Leal-Cardoso, JH; Lopes, ÉA; Nagano, CS; Rodrigues, NV; Santos, CF; Soares, CE; Sousa, PL | 1 |
| Dong, S; Li, M; Ma, G; Zhou, L | 1 |
| Cao, S; Dong, S; Li, M; Ma, G; Zhou, L | 1 |
| de Groat, WC; Ferroni, MC; Kadow, BT; Kang, A; Lyon, TD; Roppolo, JR; Shen, B; Slater, RC; Tai, C; Wang, J; Xiao, Z; Zhang, Z | 1 |
| Higashi, Y; Nakamura, K; Saito, M; Shimizu, S; Shimizu, T; Taniuchi, K; Ueba, T; Yawata, T | 1 |
| Browne, CA; Erickson, RL; Lucki, I; Robinson, SA | 1 |
| Jastrzebska, K; Przewlocki, R; Rodriguez Parkitna, J; Sikora, M; Skupio, U | 1 |
| Heller, NM; Maher, DP; Walia, D | 1 |
| D'Ângelo, MQ; Ferreira, AJ; Maltos, KLM; Pacheco, CMDF; Queiroz-Junior, CM; Soares, RV | 1 |
| Baamonde, A; González-Rodríguez, S; Lastra, A; Machelska, H; Menéndez, L; Seitz, V; Stein, C | 1 |
28 other study(ies) available for naltrexone and cyprodime
| Article | Year |
|---|---|
Synthesis and biological evaluation of 14-alkoxymorphinans. 2. (-)-N-(cyclopropylmethyl)-4,14-dimethoxymorphinan-6-one, a selective mu opioid receptor antagonist.
Topics: Animals; Guinea Pigs; In Vitro Techniques; Male; Mice; Morphinans; Narcotic Antagonists; Rats; Receptors, Opioid; Receptors, Opioid, mu | 1989 |
Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists.
Topics: Amino Acid Sequence; Analgesics; Analgesics, Opioid; Animals; Binding Sites; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Drug Design; Ligands; Models, Molecular; Molecular Sequence Data; Morphinans; Morphine; Naltrexone; Radioligand Assay; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Sequence Alignment; Structure-Activity Relationship | 2009 |
14-O-Heterocyclic-substituted naltrexone derivatives as non-peptide mu opioid receptor selective antagonists: design, synthesis, and biological studies.
Topics: Binding, Competitive; Chemistry, Pharmaceutical; Drug Design; Humans; Kinetics; Ligands; Molecular Conformation; Molecular Structure; Naltrexone; Narcotic Antagonists; Nitrogen; Peptides; Protein Structure, Tertiary; Receptors, Opioid, mu | 2009 |
Opioid receptor selectivity profile change via isosterism for 14-O-substituted naltrexone derivatives.
Topics: Molecular Conformation; Naltrexone; Narcotic Antagonists; Stereoisomerism; Structure-Activity Relationship | 2013 |
Binding mode characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives via docking in opioid receptor crystal structures and site-directed mutagenesis studies: application of the 'message-address' concept in development of mu opio
Topics: Amino Acid Sequence; Animals; Binding Sites; Cattle; Humans; Molecular Docking Simulation; Molecular Sequence Data; Mutagenesis, Site-Directed; Naltrexone; Protein Binding; Protein Structure, Tertiary; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Recombinant Proteins; Sequence Alignment | 2013 |
Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.
Topics: Animals; Behavior, Animal; Chemistry Techniques, Synthetic; CHO Cells; Cricetinae; Cricetulus; Drug Design; Male; Mice; Models, Molecular; Naltrexone; Protein Conformation; Receptors, Opioid, kappa; Receptors, Opioid, mu; Substrate Specificity | 2013 |
Differential effects of selective mu-, kappa- and delta-opioid antagonists on electroshock seizure threshold in mice.
Topics: Animals; Anticonvulsants; Bicuculline; Dose-Response Relationship, Drug; Electroshock; gamma-Aminobutyric Acid; Indoles; Male; Mice; Mice, Inbred Strains; Morphinans; Naloxone; Naltrexone; Narcotic Antagonists; Phenytoin; Receptors, Opioid; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu | 1991 |
Tonic modulation of neurotransmitter release in the guinea-pig myenteric plexus: effect of mu and kappa opioid receptor blockade and of chronic sympathetic denervation.
Topics: Acetylcholine; Animals; Colon; Dose-Response Relationship, Drug; Guinea Pigs; Morphinans; Myenteric Plexus; Naltrexone; Narcotic Antagonists; Neurotransmitter Agents; Norepinephrine; Receptors, Opioid, kappa; Receptors, Opioid, mu; Sympathetic Nervous System | 1995 |
The influence of opioid antagonists on the discriminative stimulus effects of ethanol.
Topics: Animals; Discrimination, Psychological; Dose-Response Relationship, Drug; Ethanol; Male; Morphinans; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Wistar | 1996 |
Activation of mu-opioid receptors are required for the conditioned enhancement of NK cell activity.
Topics: Animals; beta-Endorphin; Enkephalin, Leucine; Enkephalin, Methionine; Injections, Spinal; Killer Cells, Natural; Mice; Mice, Inbred BALB C; Morphinans; Naltrexone; Narcotic Antagonists; Receptors, Opioid, mu | 1996 |
Characterization of opiate binding sites on the goldfish (Carassius auratus L.) pronephric leukocytes.
Topics: Animals; Binding Sites; Goldfish; Leukocytes; Morphinans; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Receptors, Opioid, delta; Receptors, Opioid, mu | 1997 |
Relationship between inhibitory effect of endogenous opioid via mu-receptors and muscarinic autoinhibition in acetylcholine release from myenteric plexus of guinea pig ileum.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Acetylcholine; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Atropine; Electric Stimulation; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Enkephalins; Guinea Pigs; Ileum; In Vitro Techniques; Male; Morphinans; Muscarine; Muscarinic Agonists; Muscarinic Antagonists; Muscle, Smooth; Myenteric Plexus; Naltrexone; Narcotic Antagonists; Opioid Peptides; Receptors, Muscarinic; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu | 1998 |
Interactions between cholecystokinin and opioids in the isolated guinea-pig ileum.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Guinea Pigs; Ileum; In Vitro Techniques; Male; Morphinans; Muscle Contraction; Naloxone; Naltrexone; Oligopeptides; Opioid Peptides; Receptor, Cholecystokinin A; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Receptors, Opioid; Sincalide; Substance Withdrawal Syndrome | 1999 |
Use of selective antagonists and antisense oligonucleotides to evaluate the mechanisms of BUBU antinociception.
Topics: Analgesics; Animals; Male; Mice; Morphinans; Naltrexone; Narcotic Antagonists; Oligonucleotides, Antisense; Oligopeptides; Pain Measurement; Receptors, Opioid, delta; Receptors, Opioid, mu | 1999 |
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Female; Hypokinesia; Levodopa; Male; Morphinans; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Posture; Receptors, Opioid, delta; Receptors, Opioid, mu | 2001 |
[(11)C]-GR89696, a potent kappa opiate receptor radioligand; in vivo binding of the R and S enantiomers.
Topics: Adrenergic alpha-Agonists; Animals; Brain; Mice; Morphinans; Naltrexone; Narcotic Antagonists; Piperazines; Pyrrolidines; Receptors, Opioid, kappa; Stereoisomerism; Tissue Distribution | 2002 |
Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa.
Topics: Analgesics; Analgesics, Opioid; Animals; Dose-Response Relationship, Drug; Drug Tolerance; Injections, Subcutaneous; Male; Mice; Mitragyna; Models, Molecular; Morphinans; Morphine; Naloxone; Naltrexone; Narcotic Antagonists; Pain Measurement; Reaction Time; Secologanin Tryptamine Alkaloids; Substance Withdrawal Syndrome; Thailand | 2005 |
Effects of the local administration of selective mu-, delta-and kappa-opioid receptor agonists on osteosarcoma-induced hyperalgesia.
Topics: Analgesics, Opioid; Animals; Bone Neoplasms; Drug Interactions; Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; Hyperalgesia; Mice; Morphinans; Naltrexone; Narcotic Antagonists; Osteosarcoma; Receptors, Opioid | 2005 |
Opioid-like antinociceptive effects of oral administration of a lectin purified from the seeds of Canavalia brasiliensis.
Topics: Administration, Oral; Analgesics; Analgesics, Opioid; Animals; Canavalia; Mice; Morphinans; Naloxone; Naltrexone; Nociception; Pain Measurement; Plant Lectins; Receptors, Opioid, delta; Receptors, Opioid, kappa; Seeds | 2013 |
Analgesic properties of chimeric peptide based on morphiceptin and PFRTic-amide.
Topics: Analgesia; Analgesics, Opioid; Animals; Arginine; Dose-Response Relationship, Drug; Endorphins; Guinea Pigs; Male; Mice; Morphinans; Naloxone; Naltrexone; Neuropeptides; Opioid Peptides; Proline; Receptors, Neuropeptide; Tetrahydroisoquinolines; Time Factors | 2012 |
The cardiovascular effects of a chimeric opioid peptide based on morphiceptin and PFRTic-NH2.
Topics: Analgesics, Opioid; Animals; Blood Pressure; Bradycardia; Endorphins; Heart Rate; Hypotension; Injections, Intravenous; Injections, Intraventricular; Male; Morphinans; Naloxone; Naltrexone; Narcotic Antagonists; NG-Nitroarginine Methyl Ester; Rats; Rats, Wistar | 2013 |
Role of µ, κ, and δ opioid receptors in tibial inhibition of bladder overactivity in cats.
Topics: Acetic Acid; Animals; Cats; Female; Male; Morphinans; Naloxone; Naltrexone; Receptors, Opioid, delta; Receptors, Opioid, kappa; Receptors, Opioid, mu; Tibial Nerve; Transcutaneous Electric Nerve Stimulation; Urinary Bladder, Overactive | 2015 |
Brain opioid and nociceptin receptors are involved in regulation of bombesin-induced activation of central sympatho-adrenomedullary outflow in the rat.
Topics: Adrenal Medulla; Animals; Bombesin; Brain; Catecholamines; Morphinans; Naloxone; Naltrexone; Nociceptin Receptor; Rats; Receptors, Opioid; Sympathetic Nervous System | 2016 |
A role for the mu opioid receptor in the antidepressant effects of buprenorphine.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Buprenorphine; Feeding and Eating Disorders; Feeding Behavior; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Morphinans; Naltrexone; Narcotic Antagonists; Pain Measurement; Reaction Time; Receptors, Opioid, kappa; Receptors, Opioid, mu | 2017 |
Antagonism of μ-opioid receptors reduces sensation seeking-like behavior in mice.
Topics: Animals; Appetitive Behavior; Brain; Conditioning, Operant; Dose-Response Relationship, Drug; Exploratory Behavior; Male; Mice, Inbred C57BL; Morphinans; Motivation; Motor Activity; Naltrexone; Narcotic Antagonists; Random Allocation; Receptors, Opioid; Receptors, Opioid, mu; Reward | 2019 |
Suppression of Human Natural Killer Cells by Different Classes of Opioids.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics, Opioid; Anesthesia; Buprenorphine; Enkephalin, D-Penicillamine (2,5)-; Fentanyl; Fluoresceins; Humans; Immunosuppression Therapy; K562 Cells; Killer Cells, Natural; Loperamide; Methadone; Morphinans; Morphine; Naloxone; Naltrexone; Succinimides; Toll-Like Receptor 4; Tramadol | 2019 |
The blockade of kappa opioid receptors exacerbates alveolar bone resorption in rats.
Topics: Alveolar Bone Loss; Animals; Bone Resorption; Cytokines; Disease Models, Animal; Male; Morphinans; Naltrexone; Narcotic Antagonists; Osteoblasts; Osteoclasts; Periodontitis; Rats; Rats, Wistar; Receptors, Opioid | 2020 |
A low pKa ligand inhibits cancer-associated pain in mice by activating peripheral mu-opioid receptors.
Topics: Analgesics, Opioid; Animals; Bone Neoplasms; Cancer Pain; Cell Line, Tumor; Fentanyl; Hydrogen-Ion Concentration; Hyperalgesia; Ligands; Male; Melanoma, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Morphinans; Naloxone; Naltrexone; Narcotic Antagonists; Piperidines; Receptors, Opioid, mu | 2020 |